. Author manuscript; available in PMC: 2012 Nov 1.

Published in final edited form as: Cancer Prev Res (Phila). 2011 Sep 6;4(11):1761–1769. doi: 10.1158/1940-6207.CAPR-10-0343

Table 3. Study endpoints (by treatment assignment).

	Selenium	Placebo

Number randomized	227	225
Ineligible	15	14
Eligible	212	211

Endpoint status at 3 years: N (%)	77 (36.3)	77 (36.5)
EOS > 90 days out	9	18
Died	4	6
Non-PC primary cancer	4	1
Intercurrent illness	5	3
M.D. recommended no EOS biopsy	6	5
Declined EOS biopsy	21	18
Lost to follow-up	13	12
Withdrew consent	4	5
Other	11	9

Endpoint Known: N (%)	135 (63.7)	134 (63.5)
Prostate cancer: N (%)^*	48 (35.6)	49 (36.6)^*
Interim	24	22
EOS	24	27
Negative EOS biopsy: N (%)	87 (64.4)	85 (63.4)

Abbreviation: EOS, end of study.

The P-value comparing selenium versus placebo patients is 0.73 for three-year biopsy-proven carcinoma, adjusted for the stratification factors age > 60, African American, baseline PSA, and vitamin E supplementation.